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Background: Laryngeal squamous cell carcinomas (LSCCs) have a high risk
of recurrence and poor prognosis. Patient-derived cancer cell lines remain
important preclinical models for advancement of new therapeutic strategies,
and comprehensive characterization of these models is vital in the precision
medicine era.
Methods: We performed exome and transcriptome sequencing as well as copy
number analysis of a panel of LSCC-derived cell lines that were established at the
University of Michigan and are used in laboratories worldwide.
Results: We observed a complex array of alterations consistent with those reported
in The Cancer Genome Atlas head and neck squamous cell carcinoma project,
including aberrations in PIK3CA, EGFR, CDKN2A, TP53, and NOTCH family and
FAT1 genes. A detailed analysis of FAT family genes and associated pathways
showed disruptions to these genes in most cell lines.
Conclusions: The molecular profiles we have generated indicate that as a whole,
this panel recapitulates the molecular diversity observed in patients and will serve
as useful guides in selecting cell lines for preclinical modeling.
KEYWORD S
cell lines, exome sequencing, HNSCC, laryngeal cancer, precision medicine, UM-SCC
Jacqueline E. Mann and Aditi Kulkarni contributed equally to this study.
Received: 21 August 2018 Revised: 11 March 2019 Accepted: 26 April 2019
DOI: 10.1002/hed.25803
3114 © 2019 Wiley Periodicals, Inc. Head & Neck. 2019;41:3114–3124.wileyonlinelibrary.com/journal/hed
1 | INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is the
sixth most common cancer worldwide and can arise in the
oral cavity, oropharynx, hypopharynx, or larynx.1 The 5-year
survival rates for patients with HNSCC range from 40% to
80%, varying by anatomic site, tumor stage, and human papil-
lomavirus (HPV) status.2 Laryngeal squamous cell carcino-
mas (LSCCs), which comprise 20% of all HNSCCs, are
typically HPV negative and have a 5-year survival rate of
80% to 90% for stage I/II disease,3 but up to 50% of advanced
patients with LSCC experience recurrence following frontline
therapy, at which point disease progression often occurs rap-
idly with significant regression in quality of life metrics.4
Thus, robust models of LSCC are important for identification
of biomarkers distinguishing patients most likely to fail ther-
apy, as well as to develop novel treatments for aggressive dis-
ease. We believe LSCC cell line models representing the
range of cancer stages and genetic composition in both pri-
mary and recurrent/metastatic settings will aid in better under-
standing individual disease processes and responses to
treatment and in developing therapies that improve outcomes
for LSCC.
From The Cancer Genome Atlas (TCGA) project, a
molecular landscape of primary untreated LSCC is begin-
ning to emerge.5 Alterations to TP53, NOTCH1, CDKN2A,
and PIK3CA are common, whereas the presence of HPV is
relatively rare. Meanwhile, studies of recurrent and/or meta-
static LSCC suggest that with progression, the molecular
landscape shifts to contain more oncogenic lesions,6
although this relationship has not been confirmed in large
cohorts of matched primary and metastatic tumors. Regard-
less, it is clear that distribution of genetic lesions varies
among tumors, and as new questions emerge, it will be
important to interrogate them using appropriate models
within the context of genetic status. Tissue type and genetic
background will likely impact the efficacy of targeted thera-
pies, emphasizing the need for improved understanding of
the unique complexity of individual cancers.7,8
Cell lines serve as valuable tools for assessing the impact
of genetic alterations.9-12 The University of Michigan previ-
ously created a repository of HNSCC cell lines (UM-SCC)
that were characterized by short tandem repeat typing,13 and
although many of these have been utilized extensively
throughout the world, thorough genetic characterization has
not yet been performed for cell lines derived specifically
from laryngeal carcinomas.8 This limitation prevents
researchers from interpreting phenotypic and therapeutic
results in the context of tumor genetics. Thus, we aimed to
profile the genetic and transcriptomic landscape of laryngeal
UM-SCC cell lines in order to provide a molecular basis for
future studies that leverage this panel.
2 | MATERIALS AND METHODS
2.1 | UM-SCC models
LSCC cell lines were established and characterized in the
Head and Neck Oncology laboratory at the University of
Michigan with written informed consent from patient donors
with LSCC, who were treated for LSCC between 1980 and
2011. Cell lines were maintained in exponential growth
phase in Dulbecco's modified eagle medium with 10% fetal
bovine serum, 5% penicillin/streptomycin, and 5 mM nones-
sential amino acids in a 5% CO2 incubator.
In all cases except UM-SCC-105, due to the age of the
cell lines, donor tissue from either tumor or normal tissue
was unavailable for further testing.
2.2 | Exome sequencing
Exome capture library construction was performed using the
NimbleGen V2 (44.1 Mbp) Exome Enrichment kit (Roche,
Basel, Switzerland) for UM-SCC-10A, 10B, 11A, 13, 17B,
23, 25, 28, 41, 46, 76, and 81B, and paired-end sequencing
(2 × 100 bp) was performed on an Illumina Genome Analyzer
IIx Platform, with an average coverage of ×50. Library construc-
tion for UM-SCC-12 and 105 was performed using the Roche
NimbleGen V3 and paired-end sequencing (2 × 150 bp) was per-
formed on an Illumina HiSeq 4000 platform with average cover-
age of ×100. All sequencing was carried out at the University of
Michigan DNA sequencing core according to standard protocol.
Whole exomes are available through the Sequence Read Archive
(https://www.ncbi.nlm.nih.gov/sra) accession # PRJNA525437.
2.3 | Variant calling
Quality control checks were performed on the raw sequencing
data using FastQC v.0.11.5.14 Reads were aligned to hg19 refer-
ence genome using BWA v0.7.8.15 Duplicates were marked
using PicardTools v1.79 (Broad Institute, Cambridge, Massachu-
setts). BAM files were created by following the GATK best
practices workflow.16 Variants were called on each cell line
using the HaplotypeCaller producing a VCF file for each sample.
These VCFs were then combined using the GenotypeGVCFs
tool and a single VCF file was obtained for all the samples. Vari-
ant Quality Score Recalibration was applied to this joint VCF file
to filter out low quality variants. To annotate and filter the vari-
ants of interest, the commercially available tool Goldex Helix
Varseq v1.4.0 (Golden Helix, Inc., Bozeman, Montana) was
used. Filters were set as previously described.17
2.4 | Variant pathogenicity analysis
The cancer-related analysis of variants toolkit (CRAVAT;
http://www.cravat.us) was used to evaluate missense and
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indel mutations to predict pathogenicity via the variant effect
scoring tool (VEST) and driver/passenger status via the
cancer-specific high-throughput annotation of somatic muta-
tions (CHASM) tool. Missense mutations were scored with
both VEST and CHASM; indels were scored with VEST
only. The scores are used to generate P values, and a cutoff
of P < .05 was used to designate highly pathogenic (VEST)
or probable driver (CHASM) mutations.
2.5 | Sanger sequencing validation
Genomic DNA isolation was performed using the Gentra Pur-
eGene kit (Qiagen, Hilden, Germany). DNA was then poly-
merase chain reaction (PCR) amplified with Platinum Taq
DNA Polymerase High Fidelity (Invitrogen, Carlsbad, California)
following manufacturer's instructions. PCR products were cloned
into the pCR8 TOPO vector (Invitrogen) and subjected to Sanger
sequencing on a 3730XL DNA Sequencer (Applied Biosystems,
Foster City, California) at the University of Michigan DNA
Sequencing Core. Sequence alignment was performed using
the DNASTAR Lasergene software suite.
2.6 | Copy number analysis
The Affymetrix OncoScan Assay kit was used to analyze
copy number alterations in the cell lines. The CEL files pro-
duced by the kit were merged to produce OSCHP files using
the OncoScan Console v1.3 software. These OSCHP files
were then analyzed by applying the TuScan algorithm, which
is a part of the Nexus Express for OncoScan software pack-
age. From our analysis, we found a disparity between the B-
Allele Frequency plot and the copy number estimate made by
the TuScan algorithm in case of some homozygous deletion
calls (copy number = 0). To improve the accuracy of copy
number calls in these cases, we used the presence or absence
of exome sequencing reads to confirm complete loss of the
gene locus. Thus, we corrected copy number calls that were
assigned a copy number call of zero by the TuScan software,
but had exome sequencing reads, in Table S1 to indicate a sin-
gle copy of the gene. Each of these corrections was annotated
with an asterisk to denote the change. Copy number data have
been deposited in the National Center for Biotechnology
Information Gene Expression Omnibus (NCBI GEO; http://
www.ncbi.nlm.nih.gov/geo/) and are available through GEO
Series accession #GSE127231.
2.7 | Transcriptome analysis
RNA sequencing was performed for UM-SCC-10A, 10B,
12, 17B, 23, 25, 28, 46, 81A, 81B, and 105 using Illumina
stranded transcriptome library preparation kits with 75 nucleo-
tide paired end sequencing to >×100 depth on an Illumina
HiSEQ4000. Fragments per kilobase of transcript per million
mapped read were calculated as previously described,17 and
values for specific genes are listed in Table S2. Gene expres-
sion data from RNA-seq experiments have been deposited in
the NCBI GEO and are available through GEO Series acces-
sion # GSE126975.
3 | RESULTS
We performed exome sequencing and high-density arrays on
a panel of UM-SCC cell lines generated from patients with
LSCC. We analyzed 16 cell lines total, generated from
14 patients. Our panel represented a range of disease states
(stage I through stage IV LSCC) and included cell lines from
eight primary untreated, three recurrent, and four metastatic
LSCCs (Table 1). Smoking/alcohol use was reported in all
except the patient from whom UM-SCC-105 was derived,
who was HPV-18 positive.18 Two matched pairs of cell lines
were included in certain analyses: UM-SCC-10A and 10B,
derived from primary tumor and lymph node metastasis,
respectively, and UM-SCC-81A and 81B, derived from two
masses resected in separate procedures.
Comprehensive capture-based exome sequencing was per-
formed on 14 cell lines. Our analysis showed a large muta-
tional load, with approximately 30-50 nonsynonymous
mutations identified per Mb (Figure S1). To annotate the cell
line panel, we assessed common genetic aberrations previously
reported by the HNSCC TCGA consortium.5 We identified
nonsynonymous mutations affecting several of these genes,
including TP53 in 11 of 14 (79%) and FAT atypical cadherin
1 (FAT1) in 6 of 14 (43%) of cell lines (Figure 1A). Table S3
lists the specific mutations observed. Mutation rates for each
gene are provided as compared to TCGA HNSCC data.5,19
Importantly, our study lacks matched normal samples and there-
fore cannot account for germline variants, although most genes
were mutated with similar frequencies in the LSCC cell line
panel as in the TCGA tumors. Notable exceptions included FAT
and NOTCH family genes and BRCA1/2, which are mutated at
higher rates in our models than in TCGA specimens.
The FAT family mutations identified in our LSCC cell line
panel are depicted in Figure 1B and were validated by Sanger
sequencing (Figure S2). For each FAT mutation identified in
our panel, we used the VEST420-22 to predict pathogenic
impact. Variant score P values are reported for each mutation
in Figure 1B and support a pathogenic impact on FAT1 func-
tion of 5 of 7 of the identified alterations (P < .05). Interest-
ingly, FAT4 mutations were also especially prevalent, and
VEST4 scores predicted a pathogenic impact in 5 of 8 cases.
For missense mutations, the CHASM-3.1 tool was used to
predict driver mutations (Table S4). Similar analysis was
completed for the NOTCH family genes, and BRCA1/2 alter-
ations identified in our panel as these genes were altered at
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slightly higher than expected rates. Although VEST pathoge-
nicity scores for BRCA1/2 were not significant, the CHASM
predictor of tumorigenic impact classified the mutations
reported in both genes as likely driver mutations (Table S4).
After annotating molecular alterations found in the panel,
we assessed copy number alterations in 12 LSCC cell lines
via high-density single nucleotide polymorphism (SNP)
arrays to provide additional molecular detail. We first per-
formed a combined analysis of all 12 lines by summing copy
number alterations at each probe site (Figure 2A). Our analy-
sis revealed common copy number alterations in the cell line
panel consistent with those reported in previous HNSCC
studies, including broad amplifications of chromosome 3q,
5p, 7p, 8q, and 20q arms and deep deletions in the chromo-
some 3p, 8p, 9p, 11q, and 18q arms.5,23-25 Importantly, the
3q amplicon includes transcription factors TP63 and SOX2,
as well as the oncogene PIK3CA. As 35% of HNSCCs in the
TCGA study harbor an alteration in PIK3CA, it is widely
considered a potential therapeutic target, with several clinical
trials investigating PI3K inhibitors in patients with HNSCC.26
Additionally, both broad and focal deletions were observed in
the 4q35 region containing the FAT1 gene. Thus, our analysis
suggests that this panel as a whole recapitulates the landscape
of major chromosomal aberrations found in HNSCC tissues.
Next, we further interrogated our panel to characterize key
genes and pathways. Genes chosen for analysis were previ-
ously identified as commonly altered in the TCGA HNSCC
cohort,5 are otherwise implicated in HNSCC pathogenesis
(SRC, BCL6, and JAK2), or are reportedly linked to FAT1
signaling (SCRIB, STK3, WWTR1, WWC1, MTNR1A, and
FAT3). Copy number calls are reported in Table S1. Median
copy numbers are depicted in a heat map (Figure 2B, upper
panel), with numerical values provided in Table S5. We refer
to median values ≥0.5 as amplifications and values ≤−0.5 as
copy losses. Consistent with TCGA findings, we observed
amplifications of EGFR in 8 of 12 cell lines and amplifica-
tions of PIK3CA in 5 of 12. Copy losses at the CDKN2A-
CDKN2B locus were especially prevalent (10 of 12 cell lines).
We observed broad 9p deletions in 6 of 12 cell lines, with an
additional 4 cell lines exhibiting focal deletions at the
CDKN2A-CDKN2B locus (Figure 2C). We also performed
RNAseq for a subset of UM-SCC larynx cell lines
(Figure 2B, lower panel). As expected, EGFR was highly
expressed in all cell lines. In many cases, copy number alter-
ations corresponded with variations in gene expression
(Figure S3). For example, we report deletion and low expres-
sion of CDKN2A/B in UM-SCC-12 and 81A, as well as
amplification and high expression of YAP1 in UM-SCC-81B.
TABLE 1 Clinical characteristics of patients with LSCC from whom UM-SCC cell lines were derived













UMSCC-10A 57 M T3N0M0 III True cord P None 20 Heavy
UMSCC-10B 58 M rT3N1M0 III Lymph node Met S 20 Heavy
UMSCC-11A 65 M T2N2aM0 IV Epiglottis P ICX 35 Heavy
UMSCC-12 71 M T2N1M0 III Larynx R S, RT — —
UMSCC-13 60 M T3N0M0 III Stoma R RT,S 90 Heavy
UMSCC-17B 47 W T1N1M0 III Soft tissue-neck Met RT 40 None
UMSCC-23 36 W T2N0M0 II Supraglottis P None 48 Heavy
UMSCC-25 50 M rT3N2bM0 III Lymph Node Met RT,S,S Heavy Heavy
UMSCC-28 61 W T1N0M0 I True cord P None 40 —
UMSCC-41 78 M T2N1M0 III Arytenoid P None 50 Moderate
UMSCC-46 58 W T2N2M0 IV Supraglottis R RT,S 60 Heavy
UMSCC-57 69 M — — Supraglottis — — — —
UMSCC-76 66 M T3N2cM0 IV Lymph node Met ICX 40 Heavy
UMSCC-81A 53 M T2N0M0 II Anterior
commisure
P None 100 Heavy
UMSCC-81B 58 M T2N0M0 II True cord P None 100 Heavy
UMSCC-105 51 M T4N0M0 IV True cord P None HPV-18 0 None
Note: UM-SCC-10A and 10B were derived from samples taken from the same patient at different times and sites. UM-SCC-81A and 81B were derived from two vocal
cord masses resected in separate procedures. HPV-18 was detected in UM-SCC-105 by HPV-PCR mass array. HPV was not detected in other cell lines. Categories for
which no data were available are marked with a dash.
Abbreviations: HPV, human papillomavirus; ICX, induction chemotherapy; LSCC, laryngeal squamous cell carcinomas; M, men; Met, metastasis; P, primary; R,
recurrence; RT, radiation therapy; S, surgery; UM-SCC, University of Michigan squamous cell carcinoma; W, women.
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We also asked whether cell lines harboring nonsense muta-
tions likely to confer loss of function might exhibit altered
gene expression, but in this small sample size, we observed
no trends with regard to RNA expression and mutation status
(Figure S4).
FAT1 copy loss was observed in 4 of 12 cell lines in this
analysis, with focal deletions in UM-SCC-10B and 12
(Figure 2D). Notably, FAT1 was also a commonly mutated
gene in our panel (Figure 1A). Interestingly, of those cell lines
that lacked a point mutation, some (UM-SCC 10A, 10B, and
46) did exhibit FAT1 deletions, for a total of nine cell lines with
potential loss of FAT1 function. Some cell lines exhibited loss
of multiple FAT family genes: FAT1 and FAT2 losses were
both observed in the UM-SCC-10A/B pair and losses of all
four FAT genes were observed in UM-SCC-46 (Figure 2B).
However, RNA-seq indicated high expression of FAT1 in most
cell lines, with the exception of UM-SCC-10A/B.
Given the high rate of FAT1 alterations with predicted
functional impact in our panel, we sought to summarize alter-
ations in FAT family genes. FAT1 alterations occurred in 35%
of the 110 LSCCs in the TCGA cohort and 29% of the overall
cohort (Figure 3A),19 and of the 9 UM-SCC cell lines with
both copy number and single nucleotide variant data avail-
able, 7 exhibited loss of function alterations in FAT1, consis-
tent with its purported role as a tumor suppressor. About 55%
of LSCCs and 44% of all HNSCCs in the TCGA study har-
bored at least one FAT family gene alteration. Among these
samples, the majority of 110 of 143 (77%) of FAT1 mutations
are reported as truncating mutations (Figure 3A), which was
consistent with our observation of missense mutations, a
frameshift, and a stopgain among UM-SCC lines (Figure 1).
Figure 3B summarizes FAT family alterations observed in the
cell line panel. Although most FAT1 mutations were truncat-
ing or deep deletions, mutations in other FAT family members
were predominantly missense mutations in TCGA samples
and UM-SCC cell lines.
Our data support a model in which functionally recurrent
alterations to multiple genes within a pathway contribute to
overall pathway disruption. To further understand functional
recurrence of alterations to FAT signaling, we next
FIGURE 1 Single nucleotide variants identified in the laryngeal UM-SCC cell line panel. A, Nonsynonymous mutations in laryngeal UM-
SCC cell lines as called using Nimblegen capture-based exome sequencing were color coded by mutation type as indicated. Genes selected for this
analysis were previously found to be mutated in the HNSCC TCGA project5 or were otherwise of interest as common cancer-related genes (FAT,
NOTCH, and BRCA families). SNPs occurring in introns were excluded with the exception of those affecting splice sites. Also excluded were SNPs
occurring at a frequency >0.01 according to the 1000 Genomes Project. The percentage of cell lines in the LSCC panel harboring a mutation in each
gene is indicated immediately to the right. The percentage of TCGA HNSCC samples (TCGA provisional dataset) harboring a point mutation in
each gene is noted in the rightmost column (http://cancergenome.nih.gov/). B, Schematic diagrams of FAT1-4 proteins showing distribution of
mutations found in the FAT1 gene in UM-SCC laryngeal cell lines. Resulting amino acid changes are noted for each mutation next to the cell line in
which it was identified. VEST-4 pathogenicity score is indicated as a P value for each mutation. HNSCC, head and neck squamous cell carcinoma;
LSCC, laryngeal squamous cell carcinomas; TCGA, The Cancer Genome Atlas; UM-SCC, University of Michigan squamous cell carcinoma [Color
figure can be viewed at wileyonlinelibrary.com]
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examined alterations to genes linked to FAT1 signaling in
both the TCGA dataset and our cell line panel. FAT1 has
been shown to inhibit Hippo/YAP1 pathway-induced prolif-
eration and survival through its interactions with Scribble
(SCRIB) and serine/threonine kinase 3 (STK3).28-30
Figure 3C summarizes the prevalence of genetic alterations
in these genes identified in TCGA primary larynx tumors27
and all TCGA HNSCC tumors (black). From this summary,
it appears that alterations to FAT signaling are more com-
mon in LSCC than other HNSCC disease sites; in particular,
we noted that alterations affecting WWTR1, a YAP1 paralog,
were especially prevalent in larynx tumors, with 31 of
110 (28%) larynx tumors harboring a WWTR1 amplification,
compared with 39 of 394 (10%) at other subsites. Unfortu-
nately, the relatively low number of tumors from each sub-
site limits the ability to test this association statistically.
In the UM-SCC panel, we observed broad copy gains to
11q22, which contains the YAP1 gene, in 2 of 12 cell lines,
further implicating Hippo/YAP1 activation in promoting
growth and survival in these models (Figure 2B). WWTR1 is
also frequently amplified, with copy gains occurring in 6 of
12 cell lines. This is consistent with frequent WWTR1 amplifi-
cations observed in the TCGA HNSCC dataset. Figure 3D
summarizes alterations to Hippo/YAP1 pathway genes in UM-
FIGURE 2 Genetic characterization of laryngeal UM-SCC cell lines by copy number analysis. Genomic DNA was harvested from low
passage UM-SCC cell lines and analyzed using high-density SNP arrays (Affymetrix OncoScan Assay) and compared to a commercially
available pooled control. Affymetrix software was used to call copy number alterations. A, Copy number alterations were summed across UM-
SCC-10A, 10B, 12, 17B, 23, 25, 28, 46, 57, 76, 81A, 81B, and 105. Alterations for individual cell lines are shown below with gains indicated
in blue and losses indicated in red. B, Heat maps displaying median copy numbers (upper panel) and RNA expression (lower panel) for
selected genes. Key functions and relevant chromosomal regions are noted below each column. C, Focal deletions (arrow) at the CDKN2A-
CDKN2B (9p21) locus occurring in UM-SCC 12, 23, 57, and 17B. The CDKN2A gene is indicated by a bracket in the row labeled “Genes.” *,
CDKN2A;**, CDKN2B. D, Focal deletions (arrow) at the FAT1 locus (4q35) occurring in UM-SCC-10B and 12. The FAT1 locus is indicated
by a bracket and an asterisk in the row labeled “Genes.” UM-SCC, University of Michigan squamous cell carcinoma [Color figure can be
viewed at wileyonlinelibrary.com]
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SCC cell lines. Interestingly, contrary to their documented
tumor suppressive functions, amplifications of both STK3 and
SCRIB were observed in 2 of 14 and 6 of 14 cell lines, respec-
tively (Figure 2B), with modest copy gains observed in several
additional cell lines. This is consistent with the broad 8q copy
gains observed in the UM-SCC panel and TCGA data.5
Also linked to this pathway is the KIBRA protein,
encoded by WWC1, which is thought to promote the phos-
phorylation and inhibition of YAP1 and WWTR1.31 We
observed WWC1 loss in 3 of 12 cell lines, consistent with a
role in dampening Hippo/YAP1 signaling, although UM-
SCC-81A exhibits a modest copy gain. Furthermore,
NOTCH3, mutated in 5 of 14 cell lines in our mutation anal-
ysis, was recently shown to act as a tumor suppressor in
breast cancer cells by inducing KIBRA upregulation.32
Overall, the prevalence of alterations in FAT1-related genes
supports a role for Hippo/YAP1 and FAT family signaling
in these models, warranting further investigation of this net-
work in LSCC.
4 | DISCUSSION
As precision medicine protocols are developed, comprehen-
sive genetic stratification of tumors becomes increasingly
crucial to correlate with disease prognosis and to target
known driver mutations.33 Large-scale, integrated analyses
have recently provided unparalleled molecular detail toward
stratification of tumors, paving the way for precision medi-
cine protocols based upon comprehensive molecular pro-
files.5,25 To advance novel targets and combinations, an
array of well-characterized models representative of the
diversity of disease observed in the clinic must also develop
in tandem, as preliminary studies using these tools are criti-
cal to predict therapeutic response. The UM-SCC cell line
panel is widely used to model HNSCC, but genetic charac-
terization of these cell lines has been limited. Furthermore,
LSCC is a challenging clinical entity, with limited response
to current treatment modalities and poor survival rates, espe-
cially in recurrent disease.34 We therefore sought to create a
profile of UM-SCC cell lines derived from patients with
FIGURE 3 Summary of aberrations in FAT-related genes in TCGA tumors and laryngeal UM-SCC cell lines. A, Alterations reported in
TCGA provisional dataset (cbioportal.org; http://cancergenome.nih.gov) for FAT1-4. Total numbers observed for each category of mutation or copy
number variation are displayed. For each gene, the percentage of 510 tumors in the total HNSCC dataset with an alteration is reported to the left in
blue (T). The percentage of the 110 laryngeal primary tumors in this dataset harboring an alteration in each gene is reported in red (L). The
percentage of all HNSCC (blue) and LSCC (red) tumors harboring one or more mutations in any FAT gene are reported to the far left.27 B,
Alterations identified in the laryngeal UM-SCC cell line panel for FAT1-4. This analysis considers available data for all 16 cell lines in this study,
although exome sequencing was not performed for UM-SCC-57 or 81A, and copy number data are not available for UM-SCC-11A, 13, 41, or
76. C, Schematic diagram describing proposed signaling interactions involving the FAT1 protein. Percentages of HNSCC tumors bearing alterations
(amplifications, deletions, and mutations) in each gene are displayed below the gene name for LSCC only27 and the overall cohort (black). D,
Alterations identified in the laryngeal UM-SCC cell line panel for Hippo/YAP1 pathway genes. HNSCC, head and neck squamous cell carcinoma;
LSCC, laryngeal squamous cell carcinomas; TCGA, The Cancer Genome Atlas; UM-SCC, University of Michigan squamous cell carcinoma [Color
figure can be viewed at wileyonlinelibrary.com]
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LSCC to better understand these models and determine how
accurately they reflect genetic characteristics of patients.
Overall, our analysis indicates that many aberrations
recurrently identified in the HNSCC TCGA study are well
represented in the UM-SCC larynx cell line panel. EGFR,
PIK3CA, and CCND1 copy gain, CDKN2A copy loss, and
TP53 and FAT1 mutation are among the most common aber-
rations observed in our panel, consistent with reports of clin-
ical specimens. Thus, this panel appears to adequately
represent many well-studied, targetable alterations in
HNSCC and should serve as an important tool in advancing
combination therapies targeting these pathways. Importantly,
there were some genes (FBXW7, BRCA1, NOTCH2, and
NOTCH3) for which our analysis indicated considerably
higher mutation rates than those observed in the TCGA
dataset. Such discrepancies may be attributed to our small
sample size, differences in variant calling pipelines, or to the
fact that the TCGA report includes only somatic mutations,
whereas our analysis cannot distinguish somatic mutations
from germline. It is also possible that certain alterations have
been selected for during cell line derivation and culture.
Notably, significant variation in molecular profiles exists
within tumor sets and across the UM-SCC panel. For example,
UM-SCC-17B is strikingly devoid of point mutations and
copy number alterations, but harbors a PIK3CA hotspot muta-
tion at the 3:178938934 position (Table S3).35 Likewise, UM-
SCC-105, an HPV-18 positive cell line, appears similarly
genomically stable but harbors a pathogenic nonsense mutation
in BRCA2. Identification and stratification of such molecular
subsets will benefit research applications and could aid in selec-
tion of appropriate models based on patient characteristics.
Our data show an unexpectedly high prevalence of FAT1
inactivating mutations or genetic deletions and support a
deeper analysis of the pathway. Although FAT1 alterations
are well documented in HNSCC, few reports address FAT2,
FAT3, and FAT4, which have lower alteration rates than
FAT1 in the TCGA dataset (Figure 3A). In our cell line
panel, we found that FAT family alterations were prevalent
and UM-SCC-10A, 10B, and 46 harbored alterations in mul-
tiple FAT genes. We observed FAT1 and FAT2 copy loss in
the UM-SCC-10A/10B pair, along with both copy loss and
mutation in FAT4 in UM-SCC-10A. Furthermore, a FAT2
mutation with high predicted pathogenic impact was identi-
fied in both cell lines, further supporting a prominent patho-
genic role for FAT genes in these particular models.
Although FAT3 is considered paralogous to FAT1 and
exhibits similar functions,30 fewer FAT3 alterations were
discovered in the TCGA cohort, and these appeared less
likely to confer loss of function, consisting of a mix of
amplifications, deletions, missense mutations, and truncating
mutations (Figure 3A). Similarly, in the 12 cell lines sub-
jected to copy number analysis, we observed one loss and
one gain in FAT3 (in UM-SCC-46 and -25, respectively;
Figures 2B and 3B). Only three FAT3 mutations were
observed in our cell line panel and all were missense muta-
tions (Figure 1). However, UM-SCC-11A and 17B both har-
bored mutations classified as pathogenic by the VEST tool,
and the mutation in 11A is a predicted driver according to
the CHASM score. Interestingly, expression of FAT3 was
very low in most cell lines in our panel (Figure 2B). This
suggests that further dissection of FAT3 genetic alterations
may be required to understand how each type of alteration
affects FAT3 pathway activity.
When we expanded our analysis to additional genes linked
to FAT signaling, we noted frequent copy number alterations
consistent with dysregulated Hippo/YAP1 signaling, both in
our cell lines and in the TCGA dataset, particularly affecting
WWTR1. Although amplifications of purported tumor sup-
pressors STK3 and SCRIB were also observed, this may be
due to the fact that both genes are located in a broadly ampli-
fied region of 8q. Although a mechanistic role for STK3 and
SCRIB in promoting tumorigenesis has not been clearly
defined, the seemingly paradoxical overexpression of these
proteins is commonly reported in human cancers.36
FAT1 is in the cadherin class of membrane-bound proteins,
with functions that remain to be fully characterized. Notably,
FAT1 mutations may have context-dependent effects
depending on the tissue source. In HNSCC and esophageal
squamous cell carcinomas, it appears to act as a tumor sup-
pressor gene, inhibiting epithelial-mesenchymal transition and
cell proliferation,37 whereas in other tumors, it may have
oncogenic function.38,39 There is limited understanding of the
role of FAT1 in HNSCC in general, apart from the high muta-
tional rate reported in the recent TCGA study. Interestingly,
FAT1 mutant HNSCCs may have better overall survival,40
suggesting that it may portend a better prognosis for which
clinical treatment modification may be investigated. A prog-
nostic role for FAT1 will need to be investigated in confirma-
tory cohorts, and further characterization of tumors harboring
FAT1 alterations will be necessary. Recently, Martin et al
showed that FAT1 participates in assembly of a Hippo signal-
ing complex responsible for negatively regulating YAP1 in
HNSCC cell lines, thus its loss may result in unrestrained
YAP1 activity.27 Reintroduction of FAT1 intracellular
domain into FAT1 deficient cell lines resulted in decreased
YAP1 activity, reduced proliferation, and abrogated tumori-
genesis in vivo. These effects were rescued by YAP1 over-
expression. A 2017 study by Pan et al assessed YAP1 protein
by immunohistochemistry in 121 LSCC tumor samples and
found positive YAP1 expression to be associated with clinical
stage, TNM classification, lymph node metastasis, and poor
overall survival.41 Taken together, these studies support
YAP1 as a promising therapeutic target in the context of
genetic alterations in FAT1 and the Hippo signaling pathway.
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Another recent study identified a potential interaction
between FAT1 and CASP8 in oral cavity squamous cell
carcinomas,42 showing increased growth and migration in cell
lines with FAT1 loss of function, further corroborating the
functional role of FAT1 as a tumor suppressor gene. FAT1
may function as a tumor suppressor by binding to β-catenin
and blocking its nuclear translocation, thereby inhibiting Wnt
signaling pathways fundamental to growth and proliferation.38
As discussed above, FAT1 may inhibit the YAP1 pathway,
which is critical for cell growth and survival. Thus, with
FAT1 loss of function in LSCC, there may be unchecked
tumor cell growth and proliferation through both Wnt/β-
catenin and YAP1 pathways. In selecting targeted therapies in
LSCC, consideration of FAT1 status may be beneficial, as
agents inhibiting the Wnt/β-catenin pathway, many of which
are in development, may be particularly efficacious.
The UM-SCC larynx cell line panel has been in use in
laboratories throughout the world for the past several
decades. We now provide a comprehensive genetic charac-
terization of these models that can be used to contextualize
past and future studies in terms of the genetic diversity seen
in patients. However, in utilizing cell lines as model systems,
it is important to note the likelihood of variations between
stocks of the same cell line. In support of the concept that
genetic diversity exists between models cultured separately,
cytogenetic analysis was originally performed for UM-SCC-
17A/B at several different passages by Carey et al in 1989.43
There were no karyotypic differences between UM-SCC-
17A cells analyzed at passages 8, 23, 28, and 37 nor between
UM-SCC-17B cells at passages 13, 17, and 52. However, a
UM-SCC-17A subline was also discovered, differing from
the UM-SCC-17A stemline both at the cytogenetic level and
by expression of various surface antigens, including the E7
and A9 antigens. This subline was believed to represent a
distinct population present in the primary tumor, indicating
that multiple heterogeneous populations existed initially.
Furthermore, Ludwig et al performed comprehensive profil-
ing of the UM-SCC oral cavity cell line panel and provided
evidence of multiple clones through copy number analysis
and fluorescence in situ hybridization.17
The concept of cell line evolution in culture was
highlighted more recently in a comprehensive characterization
of 27 MCF7 strains in which the authors observed consider-
able variations in genetics, gene expression programs, mor-
phology, and drug response.44 Many of the cell lines
discussed here have been distributed to laboratories through-
out the world, and genetic drift and divergence among line-
ages cultured in different laboratories is highly likely. As the
purpose of the present study is to offer a baseline profile of
the LSCC cell lines, a direct comparison between the genetics
of our cell lines and lineages propagated in other laboratories
is beyond the scope of this report. However, we do describe
and reference many of the same genetic alterations reported
by other laboratories. For example, a 2018 study by Cheng
et al assessed mutations and copy number variations in a
panel of 26 HNSCC cell lines, notably including UM-SCC-
46 and UM-SC-105.45 We recapitulate many of their findings
in UM-SCC-46, such as 3q copy gain, YAP1/BIRC2 deletion,
a TP53 nonsense mutation, and KMT2D frameshift. Cheng
et al also report a 3q gain in UM-SCC-105, as well as CASP8
deletion, and so forth, which our study did not detect further
supporting the concept of potential genetic drift between
models cultured in different labs over time. Additionally,
while Cheng et al report FAT1 copy gain in nearly all cell
lines, including UM-SCC-46 and 105, our data show copy
loss in UM-SCC-46 and no alteration in UM-SCC-105.
Furthermore, Nisa et al analyzed alterations in several
UM-SCC cell line pairs in 2018, including the UM-SCC-
10A/B, 17A/B, and 81A/B pairs.46 They report several dif-
ferences between the 10A (primary tumor) and 10B (lymph
node metastasis) lines, including as a FAT4 mutation only in
10A, an observation recapitulated in our study. We also
reproduce their findings of TP53 and FAT2 mutations in
both lines, but interestingly, Nisa et al also report FAT1, 2,
and 4 mutations in UM-SCC-17B, as well as a PTEN muta-
tion in UM-SCC-81B, which we did not observe.
The present study emphasizes the utility of continuing to
expand the available array of well-characterized HNSCC cell
lines. Importantly, this report also highlights an underappre-
ciated but broad range of molecular alterations to multiple
genes associated with FAT signaling and supports a need to
deeply dissect the function of this pathway in HNSCC path-
ogenesis. As we refine our understanding of molecular com-
plexity and heterogeneity in HNSCC, our study provides a
foundation for modeling therapeutic responses and advanc-
ing personalized medicine protocols.
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